Condition: Hyperlipidemia; Mixed · Sponsor: Arrowhead Pharmaceuticals
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and effects on low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) of single-dose ARO-DIMERPA and multiple doses of ARO-DIMERPA in adult participants with mixed hyperlipidemia.
This description comes directly from the study's public registry record.
Medical Monitor · 626-304-3400 · ARODIMERPA-1001@arrowheadpharma.com
Always discuss trial participation with your own doctor first.
| Research Site 7 | Charlestown, New South Wales, Australia | Recruiting |
| Research Site 5 | Morayfield, Queensland, Australia | Recruiting |
| Research Site 8 | East Melbourne, Victoria, Australia | Recruiting |
| Research Site 4 | Melbourne, Victoria, Australia | Recruiting |
| Research Site 9 | Perth, Western Australia, Australia | Recruiting |
| Research Site 11 | Clayton, Australia | Recruiting |
| Research Site 10 | Calgary, Canada | Recruiting |
| Research Site 13 | Tbilisi, Georgia | Recruiting |
| Research Site 14 | Tbilisi, Georgia | Recruiting |
| Research Site 15 | Tbilisi, Georgia | Recruiting |
| Research Site 6 | Grafton, Auckland, New Zealand | Recruiting |
| Research Site 3 | Auckland, New Zealand | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07223658